Citations

Showing 10 of 108083 citations.

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva, Albina N. , Freudenheim, Jo L. , Eng, Kevin H., Cannioto, Rikki , Friel, Grace , Szender, J. Brian, Odunsi, Kunle , Mayor, Paul , Diergaarde, Brenda , Zsíros, Emese , Kelemen, Linda E. , Köbel, Martin , Steed, Helen , DeFazio, Anna , Jordan, Susan J. , Fasching, Peter A. , Beckmann, Matthias W. , Rossing, Mary Anne, Chang‐Claude, Jenny , Goodman, Marc T. , Dörk, Thilo , Edwards, Robert P., Ness, Roberta B., Matsuo, Keitaro , Goode, Ellen L. , Høgdall, Estrid , Schildkraut, Joellen M. , Terry, Kathryn L. , Paddock, Lisa E. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Sutphen, Rebecca , Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh , Wu, Anna H. , Kupryjańczyk, Jolanta , Jensen, Allan , Webb, Penelope M. , Moysich, Kirsten B. , Bowtell, David D.L. , Fazio, Anna de , Dörk, Thilo , Kiemeney, Lambertus A , Ramus, Susan J , Webb, Penelope M , Köbel, Martin , Jensen, Allan , Menon, Usha , Moysich, Kirsten , Matsuo, Keitaro , Kupryjanczyk, Jolanta , Høgdall, Estrid , Bowtell, David D , Segal, Brahm H. , Risch, Harvey A. , Doherty, Jennifer A. , Modugno, Francesmary , Mizuno, Mika , Karlan, Beth Y. , Kjær, Susanne K. , Cramer, Daniel W. , Bandera, Elisa V. , Anton‐Culver, Hoda , Ziogas, Argyrios , Gentry‐Maharaj, Aleksandra , Diergaarde, Brenda , Steed, Helen , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2017 | Volume: 26 | Issue: 9 | Pages: 1470-1473

10.1158/1055-9965.epi-17-0367 | PMID 28864456 Get It

Abstract Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470–3. ©2017 AACR.
Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis
Chandra, Abhishek , Wang, Luqiang, Young, Tiffany, Zhong, Leilei , Tseng, Wei‐Ju , Levine, Michael A. , Cengel, Keith A. , Pignolo, Robert J. , Qin, Ling , Liu, X. Sherry , Zhang, Yejia , Levine, M A , Chandra, Abhishek

Mayo Clinic

The FASEB Journal | August 31, 2017 | Volume: 32 | Issue: 1 | Pages: 52-62

10.1096/fj.201700375r | PMID 28860152 Get It

Bone atrophy and its related fragility fractures are frequent, late side effects of radiotherapy in cancer survivors and have a detrimental impact on their quality of life. In another study, we showed that parathyroid hormone 1‐34 and anti‐sclerostin antibody attenuates radiation‐induced bone damage by accelerating DNA repair in osteoblasts. DNA damage responses are partially regulated by the ubiquitin proteasome pathway. In the current study, we examined whether proteasome inhibitors have similar bone‐protective effects against radiation damage. MG132 treatment greatly reduced radiation‐induced apoptosis in cultured osteoblastic cells. This survival effect was owing to accelerated DNA repair as revealed by γH2AX foci and comet assays and to the up‐regulation of Ku70 and DNA‐dependent protein kinase, catalytic subunit, essential DNA repair proteins in the nonhomologous end‐ joining pathway. Administration of bortezomib (Bzb) reversed the loss of trabecular bone structure and strength in mice at 4 wk after focal radiation. Histomorphometry revealed that Bzb significantly increased the number of osteoblasts and activity in the irradiated area and suppressed the number and activity of osteoclasts, regardless of irradiation. Two weeks of Bzb treatment accelerated DNA repair in bone‐lining osteoblasts and thus promoted their survival. Meanwhile, it also inhibited bone marrow adiposity. Taken together, we demonstrate a novel role of proteasome inhibitors in treating radiation‐induced osteoporosis.—Chandra, A., Wang, L., Young, T., Zhong, L., Tseng, W.‐J., Levine, M. A., Cengel, K., Liu, X. S., Zhang, Y., Pignolo, R. J., Qin, L. Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation‐induced osteoporosis. FASEB J. 32, 52‐62 (2018). www.fasebj.org
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, Jung-Sun , Bamlet, William R. , Oberg, Ann L. , Chaffee, Kari G. , Donahue, Greg , Cao, Xing-Jun , Chari, Suresh T. , García, Benjamin A. , Petersen, Gloria M. , Zaret, Kenneth S. , Rabe, Kari G. , Kim, Jungsun , Chari, Suresh, Bamlet, William R , Cao, Xing-Jun , Chari, Suresh T

Mayo Clinic

Science Translational Medicine | August 31, 2017 | Volume: 9 | Issue: 398 | Pages: No page available

10.1126/scitranslmed.aah5583 | PMID 28701476 Get It

THBS2 and CA19-9 markers in human blood improve detection of pancreatic ductal adenocarcinoma.
Lupus‐Associated Functional Polymorphism in PNP Causes Cell Cycle Abnormalities and Interferon Pathway Activation in Human Immune Cells
Ghodke‐Puranik, Yogita , Dorschner, Jessica M., Vsetecka, Danielle, Amin, Shreyasee , Makol, Ashima , Ernste, Floranne C. , Osborn, Thomas G. , Moder, Kevin G., Chowdhary, Vaidehi , Eliopoulos, Elias , Zervou, Maria I. , Goulielmos, George N. , Jensen, Mark A. , Niewold, Timothy B. , Ernste, Floranne, Osborn, Thomas, Moder, Kevin, Makol, Ashima

Mayo Clinic

Arthritis & Rheumatology | August 31, 2017 | Volume: 69 | Issue: 12 | Pages: 2328-2337

10.1002/art.40304 | PMID 28859258 Get It

ObjectiveSystemic lupus erythematosus (SLE) is frequently characterized by activation of the type I interferon (IFN) pathway. We previously observed that a missense single‐nucleotide polymorphism (rs1049564) in the purine nucleoside phosphorylase (PNP) gene was associated with high levels of IFN in SLE. PNP is a key enzyme involved in purine metabolism. In this study, we performed functional follow‐up of this polymorphism in human cells.MethodsType I IFN was measured in patient sera, using a reporter cell assay. Structural modeling of the PNP variant was performed using PyMOL software. PNP messenger RNA (mRNA) and protein levels and type I IFN–induced gene expression were measured in lymphoblastoid cell lines with known PNP rs1049564 genotypes. The cell cycle was assayed using flow cytometry.ResultsStructural modeling indicated no major disruption in folding related to rs1049564. We observed that homozygous rs1049564 TT lymphoblastoid cells had decreased PNP mRNA expression and protein levels, and that cells with the TT genotype had reduced PNP enzymatic activity even when the amount of PNP was controlled. Cells with the TT genotype had a 2‐fold increase in S‐phase block as compared with cells with the homozygous CC phenotype. The S‐phase block could be pharmacologically reversed with hypoxanthine and adenosine, supporting the notion that relative PNP deficiency is the cause of the S‐phase block. Type I IFN–induced transcripts were increased in a dose‐response manner related to the rs1049564 T allele, at both baseline and after type I IFN stimulation.ConclusionThe PNP rs1049564 T allele is a loss‐of‐function variant that induces S‐phase block and IFN pathway activation in lymphocytes. The S‐phase block could be rescued in our in vitro experiments, suggesting the potential for personalized treatment.
Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma
Okon, Aniekan , Dawadi, Surendra , Demosthenous, Christos , Aldrich, Courtney C. , Wagner, Carston R. , Han, JingJing, Aldrich, Courtney C , Wagner, Carston R , Han, Jingjing , Gupta, Mamta

Mayo Clinic

Journal of Medicinal Chemistry | August 31, 2017 | Volume: 60 | Issue: 19 | Pages: 8131-8144

10.1021/acs.jmedchem.7b00916 | PMID 28858511 Get It

Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis
Roberts, Lewis R. , Zaiem, Feras, Almasri, Jehad , Murad, M. Hassan , Mohammed, Khaled , Roberts, Lewis R , Murad, M Hassan , Sirlin, Claude B. , Prokop, Larry J. , Heimbach, Julie K.

Mayo Clinic

Hepatology | August 31, 2017 | Volume: 67 | Issue: 1 | Pages: 401-421

10.1002/hep.29487 | PMID 28859233 Get It

Multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. To determine if there is a relative diagnostic benefit of one over the other, we synthesized evidence regarding the relative performance of CT, extracellular contrast–enhanced MRI, and gadoxetate‐enhanced MRI for diagnosis of HCC in patients with cirrhosis. We also assessed whether liver biopsy versus follow‐up with the same versus alternative imaging is best for CT‐indeterminate or MRI‐indeterminate liver nodules in patients with cirrhosis. We searched multiple databases from inception to April 27, 2016, for studies comparing CT with extracellular contrast–enhanced MRI or gadoxetate‐enhanced MRI in adults with cirrhosis and suspected HCC. Two reviewers independently selected studies and extracted data. Of 33 included studies, 19 were comprehensive, while 14 reported sensitivity only. For all tumor sizes, the 19 comprehensive comparisons showed significantly higher sensitivity (0.82 versus 0.66) and lower negative likelihood ratio (0.20 versus 0.37) for MRI over CT. The specificities of MRI versus CT (0.91 versus 0.92) and the positive likelihood ratios (8.8 versus 8.1) were not different. All three modalities performed better for HCCs ≥2 cm. Performance was poor for HCCs <1 cm. No studies examined whether adults with cirrhosis and an indeterminate nodule are best evaluated using biopsy, repeated imaging, or alternative imaging. Concerns about publication bias, inconsistent study results, increased risk of bias, and clinical factors precluded support for exclusive use of either gadoxetate‐enhanced or extracellular contrast–enhanced MRI over CT.Conclusion:CT, extracellular contrast–enhanced MRI, or gadoxetate‐enhanced MRI could not be definitively preferred for HCC diagnosis in patients with cirrhosis; in patients with cirrhosis and an indeterminate mass, there were insufficient data comparing biopsy to repeat cross‐sectional imaging or alternative imaging. (Hepatology2018;67:401‐421).
Attitudes about when and how to treat patients with AL amyloidosis: an international survey
Milani, Paolo , Gertz, Morie A. , Merlini, Giampaolo , Dispenzieri, Angela , Gertz, Morie A , Merlini, Giampaolo , Milani, Paolo , Dispenzieri, Angela

Mayo Clinic

Amyloid | August 31, 2017 | Volume: 24 | Issue: 4 | Pages: 213-216

10.1080/13506129.2017.1370421 | PMID 28857614 Get It

Decreased Shoulder External Rotation and Flexion Are Greater Predictors of Injury Than Internal Rotation Deficits: Analysis of 132 Pitcher‐Seasons in Professional Baseball
Zajac, John M., Pearson, D. B., Sinatro, Alec M., Spiker, Andrea M. , Werner, Brian C. , Altchek, David W. , Coleman, Struan H. , Camp, Christopher L. , Pearson, David B., Dines, Joshua S.

Mayo Clinic

Arthroscopy | August 31, 2017 | Volume: 33 | Issue: 9 | Pages: 1629-1636

10.1016/j.arthro.2017.03.025 | PMID 28865566 Get It

Purpose The primary aims of this work were to (1) describe normal range of motion (ROM) profiles for elite pitchers, (2) describe the characteristics of shoulder and elbow injuries in professional pitchers over a 6‐year period in one Major League Baseball organization, and (3) identify ROM measures that were independently associated with a future shoulder or elbow injury. Methods Over 6 seasons (2010‐2015), a preseason assessment was performed on all pitchers invited to Major League Baseball Spring Training for a single organization. ROM measures included shoulder flexion, horizontal adduction, external rotation (ER), internal rotation, as well as elbow flexion and extension, were measured for both the dominant and nondominant arm, and total range of motion and deficits were calculated. All noncontact shoulder and elbow injuries were identified. Using multivariate binomial logistic regression analysis to control for age, height, weight, and all other ROM measures, the factors associated with an increased risk of subsequent shoulder or elbow injury were identified. Results A total of 53 shoulder (n = 25) and elbow (n = 28) injuries occurred during 132 pitcher seasons (n = 81 pitchers). The most significant categorical risk factor associated with increased elbow injury rates was the presence of a shoulder flexion deficit >5° (odds ratio [OR] 2.83; P = .042). For continuous variables, the risk of elbow injury increased by 7% for each degree of increased shoulder ER deficit (OR 1.07; P = .030) and 9% for each degree of decreased shoulder flexion (OR 1.09; P = .017). None of the measures significantly correlated with shoulder injuries. Conclusions Preseason shoulder ER and flexion deficits are independent risk factors for the development of elbow injuries during the upcoming season. Although prior work has supported the importance of reducing glenohumeral internal rotation deficits in pitchers, this study demonstrates that deficits in shoulder ER and flexion are more significant predictors of subsequent elbow injury. Level of Evidence Level III, retrospective comparative study.
Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis
Kulik, Laura , Zaiem, Feras, Almasri, Jehad , Murad, M. Hassan , Mohammed, Khaled , Murad, M Hassan , Heimbach, Julie K. , Prokop, Larry J. , Wang, Zhen

Mayo Clinic

Hepatology | August 31, 2017 | Volume: 67 | Issue: 1 | Pages: 381-400

10.1002/hep.29485 | PMID 28859222 Get It

Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist. We conducted a comprehensive search of multiple databases from 1996 to April 25, 2016, for studies that enrolled adults with cirrhosis awaiting LT and treated with bridging or down‐staging therapies before LT. Therapies included transcatheter arterial chemoembolization, transarterial radioembolization, ablation, and radiotherapy. We included both comparative and noncomparative studies. There were no randomized controlled trials identified. For adults with T1 HCC and waiting for LT, there were only two nonrandomized comparative studies, both with a high risk of bias, which reported the outcome of interest. In one series, the rate of dropout from all causes at 6 months in T1 HCC patients who underwent LRT was 5.3%, while in the other series of T1 HCC patients who did not receive LRT, the dropout rate at median follow‐up of 2.4 years and the progression rate to T2 HCC were 30% and 88%, respectively. For adults with T2 HCC awaiting LT, transplant with any bridging therapy showed a nonsignificant reduction in the risk of waitlist dropout due to progression (relative risk [RR], 0.32; 95% confidence interval [CI], 0.06‐1.85; I 2 = 0%) and of waitlist dropout from all causes (RR, 0.38; 95% CI, 0.060‐2.370; I 2 = 85.7%) compared to no therapy based on three comparative studies. The quality of evidence is very low due to high risk of bias, imprecision, and inconsistency. There were five comparative studies which reported on posttransplant survival rates and 10 comparative studies which reported on posttransplant recurrence, and there was no significant difference seen in either of these endpoints. For adults initially with stage T3 HCC who received LRT, there were three studies reporting on transplant with any down‐staging therapy versus no downstaging, and this showed a significant increase in 1‐year (two studies, RR, 1.11; 95% CI, 1.01‐1.23) and 5‐year (1 study, RR, 1.17; 95% CI, 1.03‐1.32) post‐LT survival rates for patients who received LRT. The quality of evidence is very low due to serious risk of bias and imprecision. Conclusion: In patients with HCC listed for LT, the use of LRT is associated with a nonsignificant trend toward improved waitlist and posttransplant outcomes, though there is a high risk of selection bias in the available evidence. (H epatology 2018;67:381‐400).
Spatial Differences in Cellular and Molecular Responses as a Function of the Material Used in Conduit‐Mediated Repair and Autograft Treatment of Peripheral Nerve Injuries
Daly, William T. , Niemier, Ryan, Dillon, Simon T. , Mirsky, Rhona, Jessen, Kristján R. , Windebank, Anthony J. , Pandit, Abhay , Wang, Huan

Mayo Clinic

Advanced Functional Materials | August 31, 2017 | Volume: 28 | Issue: 12 | Pages: No page available

10.1002/adfm.201702170 Get It

AbstractThe treatment of peripheral nerve injuries remains a major problem worldwide despite the availability of a number of Food and Drug Administration (FDA) approved devices which fail to match the efficacy of autografts. Different strategies are used to improve regeneration and functional recovery using biomaterial nerve conduits. However, there is little investigation of the transcriptomic and proteomic changes which occur as a result of these interventions, particularly regarding transection injuries. This study explores differences between autograft‐mediated repair and conduit‐material‐mediated repair of peripheral nerve injuries to understand fundamental differences in their repair mechanisms at the proteomics level at the proximal, middle, and distal components in the early stages of repair. Pathway analysis demonstrates that each material selectively activates different regenerative pathways and alters different biological functions spatially throughout the biomaterial conduits. The analysis highlights some of the deficiencies in conduit‐mediated repair in comparison to autograft (e.g., recycling of myelin and cholesterol, reduction in reactive oxygen species, and higher expression of regenerative proteins). These findings thus suggest that by supplementing the expression of these proteins on the biomaterial of choice, this study can potentially attain regeneration equivalent to autograft. This approach paves the way for incorporating future biomaterial‐specific functionalities in nerve guidance conduits.